Leukocyte immunoglobulin-like receptor B1 and B4 (LILRB1 and LILRB4)

Churchill H. Leukocyte immunoglobulin-like receptor B1 and B4 (LILRB1 and LILRB4): Highly sensitive and specific markers of acute myeloid leukemia with monocytic differentiation. Cytometry B Clin. Cytom. 2020; doi: 10.1002/cyto.b.21952.

LILRB4-targeting antibody-drug conjugates for the treatment of acute myeloid leukemia

Anami Y. et al. Mol. Cancer. Ther. 2020; 19: 2330–2339.

Antagonistic anti-LILRB1 monoclonal antibody regulates antitumor functions of natural killer cells

Chen H. et al. J. Immunother. Cancer. 2020; doi: 10.1136/jitc-2019-000515.

Phagocytosis checkpoints as new targets for cancer immunotherapy

Jiang W. et al. 2012. Nature Reviews Cancer. 19 (10), 568-586.

Disrupting LILRB4/APOE interaction by an efficacious humanized antibody reverses T-cell suppression and blocks AML development

Gui X. et al. Cancer Immunol. Res. 2019; 7: 1244-1257.

Targeting the immune inhibitory receptor LILRB4 to treat acute myeloid leukemia (AML)

Zhang C. et al. Keystone Symposia on Cancer Immunotherapy: Mechanistic Insights to Improve Clinical Benefit, Whistler, BC, Canada. March 10-14, 2019.

LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration

Deng M. et al. Nature. 2018; 562: 605–609.

A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML

John S. et al. 2018. Molecular Therapy 26(10):2487-2495.

Inhibitory leukocyte immunoglobulin-like receptors: Immune checkpoint proteins and tumor sustaining factors

Kang X. et al. 2016. Cell Cycle. 15(1):25-40.

The ITIM-containing receptor LAIR1 is essential for acute myeloid leukaemia development

Kang X. et al. 2015. Nature Cell Biology 17(5):665-677.

A motif in LILRB2 critical for Angptl2 binding and activation

Deng M. et al. 2014. Blood 124(6):924-35.

Inhibitory receptors bind ANGPTLs and support blood stem cells and leukaemia development

Zheng J. et al. 2012. Nature 485:656-660